CD274 and breast carcinoma: PD-1/PD-L1 blockade is commonly employed in breast cancer trials, with FDA-approved monoclonal antibodies including Pembrolizumab, Nivolumab, Cemiplimab, Ipilimumab, Atezolizumab, Avelumab, and Durvalumab [7].